Santhera publishes pivotal trial results of idebenone and goes for EU approval


Liestal/Newscastle – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly improves vision and perception of colour in a subgroup of patients with the rare mitochondrial disease Leber's Hereditary Optic Neuropathy (LHON). The 10,000 to 20,000 patients in Europe and the US, which suffer from the maternally inherited condition, initially lose the sight in one eye due to a malfunction of complex I of the mitochondrial respiratory chain and subsequent retinal apoptosis. Typically, they lose the sight in their other eye within the next 3 to 6 months (so called discordant visual acuity). Researchers from Newcastle, Munich, and Montreal now demonstrated for the first time in 85 patients, that treatment with a 900mg dose of idebenone over two years could significantly improve visual acuity in a patient subgroup carrying the G11778A or G3460A mitochondrial DNA mutations, which are found in 80% of all LHON patients.
The Newscastle group led by Professor Patrick Chinnery reported that idebenone treatment resulted in a marked improvement of vision in severely affected patients, who were not able to read any letter on a chart. In nine blind patients (12 eyes) out of 36 patients (61 eyes) taking idebenone, vision improved to an extent that patients were able to read at least one row of letters on the chart (20%). In contrast not a single patient of the 26 who were taking the placebo improved to that extent.
The results published in yesterday’s issue of BRAIN are part of a data package accepted by the EU drug authority on July 22th which now reviews the firm’s MAA in this indication. Market approval in LHON could be expected at the end of 2012 earliest, according to the Swiss specialist for neuromuscular diseases. The drug will be available trough a Named Patient Programme until the EMA has come to a decision. The greatest improvement was seen in patients who had deteriorated in one eye more than the other. The RHODOS study does not deliver data from patients who have been affected from the disease for more than 5 years. Idebenone has already gotten market approval in Canada as treatment for Friedreichs ataxia but was rejected the the EMA in this indication.



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.03 CHF50.00%


  • NORDIC NANOVECTOR (N)25.50 NOK-5.90%
  • BIONOR PHARMA (N)0.64 NOK-5.88%
  • FORMYCON (D)20.42 EUR-5.42%


  • GALAPAGOS (B)51.78 EUR30.5%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1208.00 DKK25.4%


  • MOBERG PHARMA (S)38.40 SEK-21.0%
  • BIONOR PHARMA (N)0.64 NOK-19.0%
  • 4SC (D)2.70 EUR-18.2%


  • KARO BIO (S)29.90 SEK1880.1%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%


  • BB BIOTECH (D)44.62 EUR-84.5%
  • BIOTEST (D)17.75 EUR-77.4%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 31.05.2016


All Events


Basel (CH)

Chemspec Europe 2016